Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium
- PMID: 2852013
Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium
Abstract
The effects of saterinone [+/-)-1,2-dihydro-5-[4-[2-hydroxy-3-[4-(2-methoxyphenyl)-1-piperazinyl] propoxy] phenyl]-6-methyl-2-oxo-3-pyridine-carbonitrile, BDF 8634) on force of contraction, beating frequency, and on phosphodiesterase (PDE) activity were investigated in isolated preparations from guinea pig hearts. The effects of 3-isobutyl-1-methylxanthine (IBMX) and milrinone were studied for comparison. Saterinone exerted a concentration-dependent (1-30 mumol/l) positive inotropic effect (EC50 = 9.1 mumol/l) in guinea pig papillary muscles. The drug was more potent in increasing force of contraction than was milrinone, but its efficacy was only half as great as that of milrinone. Also IBMX revealed an about 4-fold greater positive inotropic efficacy than saterinone. This study provides functional evidence that the positive inotropic effect of saterinone is at least partially due to a cyclic adenosine monophosphate (cAMP)-dependent mechanism because carbachol antagonized the increase in force of contraction completely. In order to elucidate a possible mechanism of action of saterinone its effects on cardiac cAMP PDE activity were investigated. Saterinone selectively and potently inhibited the isoenzyme III of PDE (IC50 = 0.06 mumol/l). The mean IC50-values for the inhibition of PDE I and II were 323-fold greater. Thus, saterinone proved to be a selective inhibitor of "low-Km, cAMP specific" PDE III. Saterinone revealed only a moderate positive chronotropic effect. The beating frequency of guinea pig spontaneously beating right auricles was augmented by 26.4% at most, that is half as much as the effect of isoprenaline at a similarly effective positive inotropic concentration.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.Klin Wochenschr. 1989 Jun 15;67(12):605-15. doi: 10.1007/BF01718141. Klin Wochenschr. 1989. PMID: 2671473 Review.
-
Effects of the triazolopyrimidine trapidil on force of contraction, beating frequency and phosphodiesterase I--IV activity in guinea-pig hearts.Arzneimittelforschung. 1991 May;41(5):461-8. Arzneimittelforschung. 1991. PMID: 1716891
-
Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.Arzneimittelforschung. 1988 Sep;38(9):1287-92. Arzneimittelforschung. 1988. PMID: 2906245
-
Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.Arzneimittelforschung. 1989 Nov;39(11):1384-92. Arzneimittelforschung. 1989. PMID: 2559738
-
Pharmacology of bipyridine phosphodiesterase III inhibitors.Eur J Anaesthesiol Suppl. 1992;5:7-14. Eur J Anaesthesiol Suppl. 1992. PMID: 1600969 Review.
Cited by
-
Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.Br J Pharmacol. 1992 Sep;107(1):127-33. doi: 10.1111/j.1476-5381.1992.tb14474.x. Br J Pharmacol. 1992. PMID: 1384905 Free PMC article.
-
Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts.Naunyn Schmiedebergs Arch Pharmacol. 1994 Jun;349(6):611-8. doi: 10.1007/BF01258467. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 7526225
-
Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure.Br J Pharmacol. 1992 Feb;105(2):463-9. doi: 10.1111/j.1476-5381.1992.tb14276.x. Br J Pharmacol. 1992. PMID: 1348446 Free PMC article.
-
Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. doi: 10.1007/BF00167387. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1723153
-
Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.Klin Wochenschr. 1989 Jun 15;67(12):605-15. doi: 10.1007/BF01718141. Klin Wochenschr. 1989. PMID: 2671473 Review.